MBX Biosciences

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

MBX joins IPO queue with $100m Nasdaq filing

Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candid

News

UK partners with Eli Lilly on obesity plan

The UK has teamed up with Eli Lilly on initiatives, backed with £85 million in funding, to expand access to treatment for obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks